Exhibit (e)(7)
--------------
EMPLOYMENT AGREEMENT
--------------------
This EMPLOYMENT AGREEMENT ("Agreement"), dated as of May 4, 2000, is
entered into by and between Merck-Medco Managed Care, L.L.C. ("Merck-Medco" or
"Company"), a Delaware corporation with offices at 000 Xxxxxxx Xxxx Xxxxx,
Xxxxxxxx Xxxxx, Xxx Xxxxxx 00000 and Xxxxxxx X. Xxxxx ("Executive").
RECITALS
WHEREAS, Executive has been and is presently employed by ProVantage
Health Services, Inc. ("PV"); and
WHEREAS, PV, Merck-Medco and a subsidiary of Merck-Medco ("Merger
Sub") have entered into an Agreement and Plan of Merger, dated as of May 4, 2000
(the "Merger Agreement"), pursuant to which, at the "Effective Time" (as defined
in the Merger Agreement) (the "Effective Time"), Merger Sub will be merged with
and into PV (the "Merger") and PV will thereby become a wholly owned subsidiary
of Merck-Medco; and
WHEREAS, pursuant to the Merger Agreement, it is intended that the
acquisition of PV by Merck-Medco be accomplished by means of a cash tender offer
by Merger Sub for all of the issued and outstanding common stock of PV (the
consummation of such tender offer, the "Consummation Date"), followed by the
Merger; and
WHEREAS, Executive is currently a party to a Change of Control
Agreement with PV, dated as of December 22, 1998 (the "Change of Control
Agreement"); and
WHEREAS, Merck-Medco desires to secure the continued services and
employment of the Executive on its behalf following the Consummation Date, and
the Executive is willing to render such services on the terms and conditions set
forth herein; and
WHEREAS, the Executive and Merck-Medco have agreed that this Agreement
shall supersede the Change of Control Agreement in its entirety and that, upon
and following the Consummation Date, the Change of Control Agreement shall cease
to be of any force or effect;
NOW THEREFORE, in consideration of the mutual covenants contained
herein, the parties hereto agree as follows, effective as of the Consummation
Date:
TERMS OF AGREEMENT
In consideration of the Recitals (which are incorporated herein) and
the mutual covenants in this Agreement, the parties agree as follows:
-1-
1. Definitions. For the purpose of this Agreement, the terms used as
headings in this Section 1, and parenthetically defined elsewhere in this
Agreement, shall have the indicated meanings and may be used in the singular or
plural.
"Affiliate." Any business entity controlled by, controlling, or
under common control or in joint venture with, the Company.
"Business of the Company." The Company and/or its Affiliates are
engaged in: (i) the third party prescription drug claims processing business;
(ii) the design, development or marketing of or consulting as to, prescription
drug benefit plans; (iii) the provision of mail service pharmacy, including,
without limitation, internet-based services (including all those products and
services that are presently or hereafter marketed by the Company or any of its
Affiliates, or that are in the development stage at the time of termination of
Executive's employment and are actually marketed by the Company or any of its
Affiliates thereafter); (iv) the collection, analysis and/or sale of data
relating to prescription drug utilization; (v) the pharmacy benefit management
and disease management businesses; (vi) the organization and administration of
retail pharmacy networks; and (vii) any other business in which the Company or
any of its Affiliates is then engaged as to which Executive has involvement in
the course of his employment hereunder and/or acquired or received Confidential
Information.
"Confidential Information." All confidential and proprietary
information of the Company and its Affiliates, in whatever form, tangible or
intangible, not otherwise publicly disclosed or generally available (other than
as a result of a wrongful disclosure by the Executive), whether or not
discovered or developed by the Executive, including information entrusted to the
Company and/or its Affiliates by others. Without limiting the generality of the
foregoing, Confidential Information shall include but shall not be limited to:
(a) customer lists, lists of potential customers and details of agreements with
customers; (b) acquisition, expansion, marketing, financial and other business
information and plans of the Company or any of its Affiliates; (c) research and
development; (d) data concerning usage of prescription drugs and any other data
compiled by the Company or any of its Affiliates; (e) computer programs; (f)
sources of supply; (g) identity of specialized consultants and contractors and
Confidential Information developed by them for the Company or any of its
Affiliates; (h) purchasing, operating and other cost data; (i) special customer
needs, cost and pricing data; (j) employee information (including, but not
limited to, personnel, payroll, compensation and benefit data and plans); and
(k) patient records and data, including all such information recorded in
manuals, memoranda, projections, minutes, plans, drawings, designs, formula
books, specifications, computer programs and records, whether or not legended or
otherwise identified by the Company or any of its Affiliates as Confidential
-2-
Information, as well as such information that is the subject of meetings and
discussions and not recorded.
"Developments." All data, discoveries, findings, reports,
designs, inventions, improvements, methods, practices, techniques, developments,
programs (computer or otherwise), formulas, plans, concepts, and ideas, whether
or not patentable, relating to the present and planned future activities and the
Products and Services of the Company or any of its Affiliates.
"Employment Period." The period from the Consummation Date (the
"Commencement Date") through the second anniversary of the Commencement Date
(or, if later, through the second anniversary of the Effective Time), unless
terminated prior thereto as set forth in Section 6.
"Products and Services." All products or services sold, rented,
leased, rendered or otherwise made available to customers by the Company or any
of its Affiliates, as well as products and services in any stage of development
by the Company or any of its Affiliates, although not yet commercialized or not
generally available.
"Territory." The United States of America, its territories and
possessions.
2. Employment. The Company hereby employs the Executive during the
Employment Period subject to the terms of this Agreement, and thereafter as an
employee-at-will, and to perform those duties and services as may be designated
from time-to-time by its President or his designee. Executive hereby accepts
said employment. The Executive shall use his best and most diligent efforts to
promote the interests of the Company and its Affiliates and shall devote his
full business time and attention to his employment under this Agreement. The
Executive will not, without the prior written approval of the President of
Merck-Medco, engage in any other business activity which would interfere with
the performance of his duties, services and responsibilities hereunder or which
is in violation of policies established from time to time by Merck-Medco. It is
understood that the Executive is Chair-Elect of PCMA and will serve as Chair of
that association.
3. Title. The Executive presently has been assigned the title of
President and Chief Executive Officer - ProVantage. In the future, the Company
may assign the Executive to other positions and titles, as required by the
Company's business.
4. Compensation and Benefits; Disability.
4.1 Base Compensation. During the Employment Period, the Company
shall pay the Executive base compensation commencing at an annual rate of
$449,350.00; the Executive shall be eligible for annual merit increases at the
discretion of the Company. Such base compensation shall be payable in equal
installments pursuant to the Company's customary payroll policies in force at
the time of payment (but not less frequently than monthly). Such base
-3-
compensation and any other payments made hereunder shall be less all required
and/or authorized payroll deductions.
4.2 Retention Arrangement. Not later than the close of business
on May 15, 2000, the Executive shall notify the Company substantially in the
form of the notice attached hereto as Exhibit A that he has irrevocably elected
one of the Retention Arrangements set forth therein. If the Executive fails to
provide timely notice to the Company substantially in form of the notice
attached hereto as Exhibit A, the Executive will be deemed to have elected
Retention Arrangement No. 1 described in the form of notice attached as Exhibit
A. Lump sum payments payable to the Executive hereunder shall be payable
(subject to applicable withholding) as soon as practicable after the second
anniversary of the Consummation Date (or, if later, after the second anniversary
of the Effective Time), so long as the Executive has remained an employee of
Merck-Medco through the entire Employment Period and is an employee of Merck-
Medco on the second anniversary of the Consummation Date (or, if later, after
the second anniversary of the Effective Time).
4.3 Incentive Bonus and Stock Options. In addition to the
Retention Arrangement set forth in Paragraph 4.2, the Executive shall be
eligible to receive the following during the Employment Period:
(a) Bonus. During the Employment Period, the Executive shall be
eligible to receive performance-based bonuses on the same
terms and conditions generally afforded other similarly
situated employees of Merck-Medco under the Merck & Co.,
Inc. Annual Incentive Plan.
(b) Stock Options. Any options granted in connection with the
applicable Retention Arrangement set forth on Exhibit A
attached hereto shall be subject to the terms and conditions
set forth in Exhibit B attached hereto and made a part
hereof. During the Employment Period, the Executive will be
eligible to receive other grants of options to purchase
shares of Merck & Co., Inc. common stock under the Merck &
Co., Inc. Incentive Stock Plan (the "Merck Stock Plan") at
an exercise price equal to the fair market value of such
common stock on the date of grant. The number of shares
covered by any such option shall be determined by the
Company in its sole and absolute discretion. All the terms
and conditions of such options shall be governed by the
terms and conditions of the Merck Stock Plan in effect at
the time of the applicable grant, as summarized in the
option grant letter provided to the Executive at the time of
each such option grant, which terms and conditions shall be
the same as those that apply to similarly situated employees
of Merck-Medco at the time of such grant.
4.4 Other Benefits. During the Employment Period, the Executive
shall be eligible to participate in the employee benefit plans and programs of
the Company, including, but
-4-
not limited to, its medical, dental, disability, life insurance and retirement
benefit plans and programs of the Company on the same terms and conditions as
are generally afforded similarly situated employees of the Company, subject to
any contribution requirements applicable to participants of such plans and
programs.
4.5 Vacation. The Executive may take such vacation period or
periods during each year in accordance with the Company's vacation policies or
practices for similarly situated employees of the Company. Prior employment with
PV shall be considered as employment with the Company for this purpose.
5. Expenses. Pursuant to the Company's customary policies in force
at the time of payment, the Executive shall be promptly reimbursed, against
presentation of vouchers or receipts therefor, for all expenses properly and
reasonably incurred by him on behalf of the Company and its Affiliates in the
performance of his duties hereunder.
6. Termination of Employment Period. This Agreement shall continue
through the Employment Period, unless terminated prior to such date by the
earlier of (a) the Executive's termination pursuant to Sections 7.1, 7.2, 7.3 or
7.5; or (b) the Executive's death. In all events, the provisions of Section 9
shall survive termination of this Agreement, and shall remain in effect during
and after any continued employment by the Company subsequent to the termination
of the Employment Period.
7. Termination.
7.1 By the Company for Cause. Upon written notice, the Company
may discharge the Executive and terminate this Agreement for Cause. As used in
this Section 7, Cause shall mean any one or more than one of the following: (i)
an act or acts of personal dishonesty or misrepresentation taken by the
Executive and intended to result in substantial personal enrichment of the
Executive at the expense of the Company; (ii) repeated violations by the
Executive of the Executive's obligations under this Agreement which are
demonstrably willful and deliberate on the Executive's part and which are not
remedied within thirty (30) days after receipt of notice from the Company, or
(iii) the conviction of the Executive of a felony.
7.2 By the Company Without Cause or By the Executive for Good
Reason. The Company on written notice to the Executive may discharge the
Executive and terminate this Agreement without Cause at any time during the
Employment Period. The Executive may terminate this Agreement during the
Employment Period for "Good Reason," which shall mean any one of the following:
(i) the Executive's transfer to a place of employment more than fifty (50) miles
from the Executive's current place of employment; or (ii) a reduction in the
Executive's job title from the title currently specified in paragraph 2 of this
Agreement; however, Executive may terminate the Employment Period for Good
Reason only after the passage of sixty (60) days following written notice from
the Executive to the Company of the event giving rise to the Termination and a
failure by the Company to cure such event.
-5-
7.3 Disability. If during the Employment Period, (i) the
Executive shall become ill, mentally or physically disabled, or otherwise
incapacitated so as to be unable to perform regularly the duties of his position
for a period in excess of 90 consecutive days or more than 120 days in any
consecutive 12 month period, or (ii) a duly licensed physician (who does not
have any business or other previous relationship with the Company and is
associated with a teaching hospital in the New York City metropolitan area)
selected by the Company determines that the Executive is mentally or physically
disabled so as to be unable to perform regularly the duties of his position and
such condition is expected to be of a permanent duration (each a "Permanent
Disability"), then the Company shall have the right to discharge the Executive
and terminate this Agreement upon 30 days' written notice to the Executive. In
the absence of termination, the Executive shall receive full compensation and
benefits while disabled; provided, however, that any payments to the Executive
pursuant to the Company's disability plans shall be offset from amounts payable
to the Executive under this Paragraph 7.3. Upon a request by the Company, the
Executive will submit to a medical examination to determine whether the
Executive is subject to a Permanent Disability.
7.4 Death. The Employment Period and this Agreement shall
terminate forthwith upon the death of the Executive.
7.5 By the Executive. The Executive may terminate the Employment
Period and this Agreement at any time upon 30 days' written notice to the
Company for any reason other than Good Reason. Section 7.2 shall be the sole
basis for termination for Good Reason.
8. Effect of Termination.
8.1 Effect of Termination under Section 7.1. In the event of
termination of this Agreement by the Company pursuant to Section 7.1, the
Executive shall be entitled to receive only his earned and unpaid compensation
to the effective date of such termination.
8.2 Effect of Termination under Section 7.2. In the event of
termination of this Agreement during the Employment Period pursuant to Section
7.2, the Executive shall be entitled to:
(a) receive his earned and unpaid compensation to the effective
date of such termination;
(b) a lump sum payment in the amount of $675,000 (less
applicable withholding) in consideration of the covenants of
the Employee set forth in Section 9 below (and subject in
any event to the last sentence of Section 9.6 hereof);
(c) an additional lump sum payment in the amount of $834,837.00
(less applicable withholding);
-6-
(d) 1/24th of the amount equal to the remainder, if any, of (x)
the lump sum amount, if any, that would have been payable
under the Retention Arrangement the Executive elects
pursuant to Section 4.2 and (y) $1,698,567 for each full
calendar month during which the Executive actually performs
services for the Company (less applicable withholding); and
(e) Continued coverage (in an inactive, unpaid employee status)
under the Company's medical, dental and prescription plans
for twelve (12) months or until the Executive obtains other
employment with comparable coverages, whichever is earlier.
8.3 Effect of Termination under Sections 7.3 or 7.4. In the
event of termination of this Agreement during the Employment Period pursuant to
Sections 7.3 or 7.4, the Executive (or the personal representative of his estate
or his heirs at law, as appropriate, in the case of a termination pursuant to
Section 7.4) shall be entitled to the amounts referred to in Sections 8.2(a)
through 8.2(c) of this Agreement. In addition, in the event of a termination of
this Agreement during the Employment Period pursuant to Section 7.4, and so long
as the Executive has elected Retention Arrangement No. 1 or Retention
Arrangement No. 3 described on Exhibit A attached hereto, the Executive's estate
or heirs at law, as appropriate, shall be entitled to an amount equal to the
excess of the lump sum payment payable under the applicable Retention
Arrangement over the lump sum payments payable under Sections 8.2(b) and 8.2(c)
(less applicable withholding).
8.4 Effect of Termination Under Section 7.5.
(a) In the event of Termination of this Agreement under Section
7.5 within the first six months of the Employment Period, the Executive shall be
entitled to receive only his earned and unpaid compensation to the effective
date of such termination.
(b) In the event of Termination of this Agreement under Section
7.5 after the first six months of the Employment Period have elapsed, but before
the expiration of the Employment Period, the Executive shall be entitled to
receive:
(i) his earned and unpaid compensation to the effective
date of such termination; and
(ii) a lump sum payment in the amount of $675,000 (less
applicable withholding) in consideration of the covenants of the
Employee set forth in Section 9 below (and subject in any event
to the last sentence of Section 9.6 hereof);
(iii) an additional lump sum payment in the amount of
$834,837.00 (less applicable withholding).
-7-
8.5 Conditions Applicable to Sections 8.2, 8.3 and 8.4. Any
payments required under Section 8.2, 8.3 or 8.4 will be conditioned upon the
Executive (or the personal representative of his estate or his heirs at law, as
appropriate) executing and delivering a general release of the Company and its
Affiliates, and their Managers, officers, employees and agents, from any claims
or obligations other than (i) the expressed obligation of the Company under
Section 8.2, 8.3 or 8.4 of this Agreement, as appropriate, (ii) to pay the
Executive his earned and unpaid compensation to the effective date of
termination, (iii) the obligations of the Company and its Affiliates with
respect to all Stock Options, (iv) the obligations of the Company and its
Affiliates to continue to provide director and officer indemnification (if
applicable) and (v) the obligations of the Company and its Affiliates to comply
with the requirements of COBRA and any other law or regulation applicable to
employee benefit plans in connection with the termination of employment
generally. Such general release shall be in a form acceptable to the Company.
The Executive acknowledges that the payments under Section 8.2, 8.3 or 8.4, as
appropriate, are in lieu of all such released claims that the Executive may have
against the Company and are liquidated damages (and not a penalty).
Notwithstanding any termination hereunder, the Company shall have no obligation
under Section 8.2, 8.3 or 8.4 in the event of a material breach by the Executive
of his covenants in Section 9. For purposes of this Section 8, the term Stock
Options shall mean all options to purchase common stock of Merck & Co., Inc.
previously or hereafter granted to the Executive by the Company and/or any of
its Affiliates.
8.6 Consulting Period. In the event of (i) termination of this
Agreement at any time before the expiration of the Employment Period in
connection with the termination of the Executive's employment by the Company
without Cause or by the Executive with Good Reason under Section 7.2, or (ii)
termination of the Agreement after the first six months of the Employment Period
have elapsed but before the expiration of the Employment Period in connection
with termination of the Executive's employment by the Executive for any reason
other than Good Reason under Section 7.5, the Executive will be retained as a
Consultant by the Company for a period of four (4) months commencing on the date
of Termination of his employment (the "Consulting Period"). During the
Consulting Period, the Executive will make himself available to provide services
to the Company at the Company's reasonable request, and at mutually agreeable
times and places, for not less than 40 hours per month. As compensation for
these consulting services, the Executive will receive payments in the amount of
$47,182.42 per month during the Consulting Period (less any applicable
withholding).
9. Developments, Confidential Information and Related Matters.
9.1 Assignment of Developments. All Developments that are at any
time made, conceived or suggested by the Executive, whether acting alone or in
conjunction with others, during or as a result of the Executive's employment
under this Agreement or thereafter, shall be the sole and absolute property of
the Company, free of any reserved or other rights of any kind on the Executive's
part. During the Executive's employment by the Company and thereafter, the
Executive shall promptly make full disclosure of any such Developments to the
Company and, at its cost and expense, do all acts and things (including, among
others, the execution and delivery under oath of patent and copyright
applications and instruments of assignment) deemed
-8-
by the Company to be necessary or desirable at any time in order to effect the
full assignment to the Company of the Executive's right and title, if any, to
such Developments.
9.2 Restrictions on Use and Disclosure. The Executive
acknowledges that the Confidential Information is valuable and proprietary to
the Company (or to third parties that have entrusted Confidential Information to
the Company), and, except as required by the Executive's duties hereunder, the
Executive shall not at any time, directly or indirectly, use, copy, publish,
summarize, disseminate, describe or otherwise disclose any Confidential
Information or Developments without the prior written consent of the Company.
9.3 Return of Documents. Upon termination of the Executive's
employment with the Company, or at the Company's request, whichever is sooner,
the Executive shall forthwith deliver to the Company all manuals, memoranda,
projections, minutes, plans, drawings, designs, formula books, specifications,
listings, records, notebooks, computer programs and similar repositories of, or
containing Confidential Information and Developments, including all copies, then
in the Executive's possession or control, whether prepared by the Executive or
others. Upon such termination, the Executive shall not retain any copies or
abstracts of any such documents or materials.
9.4 Restrictions on Competitive Employment. During the term of
the Executive's employment and for a period of twelve (12) months after the
termination of the Executive's employment for any reason, pursuant to this
Agreement or thereafter, absent the Company's prior written approval, the
Executive shall not (as an individual, principal, agent, employee, consultant or
otherwise) within the Territory, directly or indirectly, engage in activities
competitive with, nor render services to any firm or business engaged or about
to become engaged in the Business of the Company. In addition, the Executive
shall not have an equity interest in any such firm or business other than as a
1% or less shareholder of a public corporation.
9.5 Inducement; Enticement. During the term of the Executive's
employment and for a period of twelve (12) months after the termination of the
Executive's employment for any reason, pursuant to this Agreement or thereafter,
the Executive shall not, directly or indirectly: (a) solicit or contact any
customer or prospective customer of the Company or any of its Affiliates as to
matters that relate to the Business of the Company or which is in any way
inconsistent or interferes therewith; (b) induce, or attempt to induce, any
employees or agents or consultants of the Company or any of its Affiliates to do
anything from which the Executive is restricted by reason of Sections 9.1
through 9.5; or (c) offer or aid others to offer employment to any employees of
the Company or any of its Affiliates.
9.6 Survival and Other Matters. The provisions of Sections 9.1
through 9.5 shall survive the termination of this Agreement and shall continue
in effect during and after any employment of the Executive after the end of the
Employment Period and the termination of this Agreement. This provision shall
not be construed to limit the survival of any other provisions that also survive
the termination of this Agreement by the express or implied terms of such
provisions. In addition, it is understood that the value to the Company of the
Executive agreeing
-9-
to and abiding by the restrictions set forth in this Section 9 is equal to at
least $675,000, but it is further understood that (i) the Executive has agreed
to abide by such restrictions in consideration of the Company's entering into
this Agreement, and (ii) such restrictions shall remain in effect irrespective
of whether the Executive becomes entitled to any payments or benefits hereunder.
10. Notices. All notices and other communications provided for or
permitted hereunder shall be in writing and shall be deemed to have been duly
given on the date that they are delivered personally or sent by registered or
certified mail (return receipt requested) postage prepaid to the parties at the
following addresses (or at such other address for any party as shall be
specified by like notice, provided that notices of a change of address shall be
effective only upon receipt thereof):
(a) If to the Company:
Merck-Medco Managed Care, L.L.C.
000 Xxxxxxx Xxxx Xxxxx
Xxxxxxxx Xxxxx, Xxx Xxxxxx 00000
Attention: Senior Vice President -
Chief Financial Officer
With a copy at the same address to:
President.
(b) If to the Executive, at the last address included on the
Company's payroll records.
11. [intentionally omitted.]
12. Miscellaneous.
12.1 Representations and Covenants. In order to induce the
Company to enter into this Agreement, the Executive makes the following
representations and covenants to the Company and acknowledges that the Company
is relying upon said representations and covenants:
(a) No agreements or obligations exist to which the Executive is
a party or otherwise bound, in writing or otherwise, which
in any way interfere with, impede or preclude him from
fulfilling all of the terms and conditions of this
Agreement.
(b) The Executive, during his employment by the Company, shall
use his best efforts to disclose to the President in writing
or by other effective method any bona fide information known
by him that
-10-
would have any material negative impact on the Company or an
Affiliate.
12.2 Entire Agreement. This Agreement contains the entire
understanding of the parties as to the subject matter hereof and fully
supersedes all prior oral and written agreements and understandings between the
parties with respect to such subject matter. This Agreement also supersedes and
nullifies any and all change-of-control, severance or other employment-related
agreements entered into by Executive with PV or any of its predecessor or
affiliated corporations (including, without limitation, the Change of Control
Agreement), it being agreed between Executive and Merck-Medco that, following
the Consummation Date, (i) the consideration provided to the Executive as set
forth in this Agreement is in lieu of any consideration provided by such other
agreements and (ii) all such agreements shall cease to be of any force and
effect.
12.3 Amendment; Waiver. This Agreement may not be amended,
supplemented, cancelled or discharged, except by written instrument executed by
the party as to whom enforcement is sought. No failure to exercise, and no delay
in exercising, any right, power or privilege hereunder shall operate as a waiver
thereof. No waiver of any breach of this Agreement shall be deemed to be a
waiver of any preceding or succeeding breach of this Agreement.
12.4 Binding Effect; Assignment. The rights and obligations of
this Agreement shall bind and inure to the benefit of the surviving corporation
in any merger or consolidation in which the Company is a party, or any assignee
of all or substantially all of the Company's business and properties. The
Executive's rights and obligations under this Agreement may not be assigned by
him, except that his right to receive accrued but unpaid compensation,
unreimbursed expenses and other rights, if any, provided under this Agreement
which survive termination of this Agreement shall pass after death to the
personal representatives of his estate.
12.5 Headings. The headings contained in this Agreement (except
those in Section 1) are for reference purposes only and shall not affect the
meaning or interpretation of this Agreement.
12.6 Counterparts. This Agreement may be executed in one or
more copies, each of which shall be deemed an original.
12.7 Governing Law; Interpretation. This Agreement shall be
construed in accordance with and governed for all purposes by the laws and
public policy of the State of New Jersey, without regard to any principles of
conflict of laws. Service of process in any dispute shall be effective (a) upon
the Company, if served upon the Chairman of the Board, the President or any
Executive Vice President of the Company (other than the Executive); and (b) upon
the Executive, if delivered to the Executive's residence last known to the
Company. The Executive acknowledges that a breach of Sections 9.1 through 9.5
would cause grave and irreparable injury to the Company that would not be
compensable in money damages, and therefore, in addition to the Company's other
express and implied remedies, the Company shall be entitled to injunctive
-11-
and other equitable relief to prevent any actual, intended or likely injuries
that may result from such breach. However, nothing in this Section shall limit
any other right or remedy to which the Company may be entitled.
12.8 Further Assurances. Each party agrees at any time, and
from time-to-time, to execute, acknowledge, deliver and perform, and/or cause to
be executed, acknowledged, delivered and performed, all such further acts,
deeds, assignments, transfers, conveyances, powers of attorney and/or assurances
as may be necessary, and/or proper to carry out the provisions and/or intent of
this Agreement.
12.9 Gender; Singular; Plural. In this Agreement, the use of one
gender (e.g., "he", "she" and "it") shall mean each other gender; and the
singular shall mean the plural, and vice versa, all as the context may require.
12.10 Severability. The parties acknowledge that the terms of
this Agreement are fair and reasonable at the date signed by them. However, in
light of the possibility of a change of conditions or differing interpretations
by a court of what is fair and reasonable, the parties stipulate as follows: if
any one or more of the terms, provisions, covenants or restrictions of this
Agreement shall be determined by a court of competent jurisdiction to be
invalid, void or unenforceable, the remainder of the terms, provisions,
covenants and restrictions of this Agreement shall remain in full force and
effect and shall in no way be affected, impaired or invalidated; further, if any
one or more of the terms, provisions, covenants or restrictions contained in
this Agreement shall for any reason be determined by a court of competent
jurisdiction to be excessively broad as to duration, geographical scope,
activity or subject, it shall be construed, by limiting or reducing it, so as to
be enforceable to the maximum extent compatible with then applicable law.
12.11 Consents. Any consent, approval or authorizations
required hereunder shall mean the written consent, approval or authorization of
the Chairman of the Board of the Company or such other officer as may be
designated in writing by the Board of Managers.
EXECUTION
The parties, intending to be legally bound in accordance with its terms
as of the date first above written, executed this Agreement, to be effective as
of the Consummation Date.
MERCK-MEDCO MANAGED CARE, L.L.C.
DATE: May __, 2000 /s/ Xxxxxxx X. Xxxxx
--------------------------------
By: Xxxxxxx X. Xxxxx
Its: President
DATE: May __, 2000 /s/ Xxxxxxx X. Xxxxx
--------------------------------
Xxxxxxx X. Xxxxx
-12-
Exhibit A to Employment Agreement
NOTICE OF RETENTION ARRANGEMENT ELECTION
----------------------------------------
Date: _______________, 2000
Certified Mail/Return Receipt Requested
Xx. Xxxxxx XxXxxxxx
Senior Vice President - Human Resources
Merck-Medco Managed Care, L.L.C.
000 Xxxxxxx Xxxx Xxxxx
Xxxxxxxx Xxxxx, Xxx Xxxxxx 00000
Dear Xx. XxXxxxxx:
Pursuant to Section 4.2 of that certain employment agreement (the
"Employment Agreement") dated __________, 2000 between me and Merck-Medco
Managed Care, L.L.C. (the "Company"), I hereby irrevocably elect the Retention
Arrangement indicated by a check xxxx below:
[_] Retention Arrangement No. 1
A lump sum payment of $2,264,756.00
[_] Retention Arrangement No. 2
(A) A lump sum payment of $1,698,567.00; and
(B) an option to purchase 40,442/1/ shares of Merck & Co., Inc.
common stock under the Merck Stock Plan, on the terms set forth
on Exhibit B attached to the Employment Agreement, which option
shall be granted at the Consummation Date, provided I am an
employee of Merck-Medco on that date.
[_] Retention Arrangement No. 3
(A) A lump sum payment of $1,981,662.00; and
(B) an option to purchase 20,221 shares of Merck & Co., Inc. common
stock under the Merck Stock Plan, on the terms set forth on
Exhibit B attached to the Employment Agreement, which option
shall be granted at the
-------------------
/1/ The number of shares subject to the option referenced in subparagraph
(B) of Retention Arrangement Nos. 2 and 3 is an estimate based upon a closing
price of $70.00 per share. The actual number of shares subject to the option may
vary.
-14-
Consummation Date, provided I am an employee of Merck-Medco on
that date.
I understand, acknowledge and agree that:
(1) The Retention Arrangement I have irrevocably elected above is
subject to the terms and conditions set forth in the Employment
Agreement and that nothing in this letter agreement in any way
affects the terms and conditions of the Employment Agreement;
(2) Upon execution of this letter agreement by me and the Company,
this letter agreement shall be incorporated into and deemed a
part of the Employment Agreement;
(3) This letter agreement may be executed in one or more copies, each
of which shall be deemed an original; and
(4) Capitalized terms not specifically defined herein shall have the
meaning ascribed to them in the Employment Agreement.
Please indicate your election, and your agreement with and acceptance
of the foregoing, by executing a copy of this letter agreement below as
indicated.
Sincerely,
______________________
Xxxxxxx X. Xxxxx
Agreed to and accepted this ___ day of
_________, 2000
Merck-Medco Managed Care, L.L.C.
By:________________________
Name:______________________
Title:_______________________
-15-
Exhibit B to Employment Agreement
Option Terms
------------
-------------------------------------------------------------------------------------------------
Option Type: Non-qualified stock option
-------------------------------------------------------------------------------------------------
Term: 10 years from date of grant (the "Expiration
Date")
-------------------------------------------------------------------------------------------------
Vesting Date: Earlier of date of death and 2nd anniversary of
grant date, provided the Executive is an
employee of Merck-Medco on the applicable date
-------------------------------------------------------------------------------------------------
Exercise Price: Fair market value on date of grant
-------------------------------------------------------------------------------------------------
Effect of termination of Employment: see chart below
-------------------------------------------------------------------------------------------------
Effect of Termination of Employment:
-----------------------------------
------------------------------------------------------------------------------------------------------------------
Due to death options are exercisable by the estate for 3 years from
date of death (but not later than the Expiration Date)
------------------------------------------------------------------------------------------------------------------
By the Company for "Cause" (as defined in the options lapse on the termination of employment date
Employment Agreement).
------------------------------------------------------------------------------------------------------------------
By the Company without Cause (other than death) or by Options to purchase a number of shares equal to the
the Executive for "Good Reason" (as defined in the product (rounded to the nearest whole number) of (a) the
Employment Agreement) during the 2-year period total number of shares subject to the option multiplied
beginning on the date of grant. by (b) a fraction, the numerator of which is the number
of full calendar months the Executive has been employed
by the Company (excluding any period the Executive is on
unpaid inactive status due to the application of
Paragraph 8.2(e) of the Employment Agreement) since the
option grant date and the denominator of which is 24,
are exercisable by the Executive for a period beginning
on the date the Executive's active employment with the
Company is terminated and ending on the 5th anniversary
of the grant date. The remaining options lapse on the
date the Executive's active employment with the Company
terminates. For purposes of this section, the
Executive's active employment ends on the earlier of (x)
the date his employment terminates or (y) the day his
period of unpaid inactive employment with the Company
begins in accordance with Paragraph 8.2(e) of the
Employment Agreement.
------------------------------------------------------------------------------------------------------------------
By the Executive for any reason (other than death or options lapse on termination of employment date
Good Reason) during the 2-year period beginning on
date of grant
------------------------------------------------------------------------------------------------------------------
-16-
------------------------------------------------------------------------------------------------------------------
By the Company without cause (other than death or options are exercisable for the following period,
disability) during the period beginning on the 2nd whichever is longer: (a) 3 months from the termination
anniversary of grant date and ending on the 5th of employment date or (b) 5th anniversary of grant date
anniversary of grant date
------------------------------------------------------------------------------------------------------------------
By the Executive for any reason (other than death) or options are exercisable for 3 months from termination of
by the Company for disability, in each case during employment date
the period beginning on the 2nd anniversary of grant
date and ending on the 5th anniversary of grant date
------------------------------------------------------------------------------------------------------------------
By the Company due to "separation" (as defined by the options are exercisable for 1 year from termination of
Merck Stock Plan) during the period beginning on the employment date (but not later than the Expiration Date)
5th Anniversary and ending on the Expiration Date
------------------------------------------------------------------------------------------------------------------
By the Executive due to retirement at or after age 55 options are exercisable until the Expiration Date
with at least 7 years of employment with Merck-Medco
during the period beginning on the 5th Anniversary
and ending on the Expiration Date
------------------------------------------------------------------------------------------------------------------
By the Company or Executive for any reason (other than options are exercisable for 3 months from termination of
death, separation or retirement) during the period employment date (but not later than the Expiration Date)
beginning on the 5th Anniversary and ending on the
Expiration Date
------------------------------------------------------------------------------------------------------------------
-17-
